Healthcare Insights Neurostimulation Devices Market | Page 2

©2019 Transparency Market Research, All Rights Reserved
Technological Advancements and New Product Development to Propel
Market
 Rise in the demand for neurostimulation devices owing to unmet
medical needs and demand for improved product outcomes and
efficiency have led to the development of innovative products and
technologies to address the unmet needs of patients as well as
surgeons. In order to provide improved and alternative solutions to
unmet medical needs in neurological disorders, companies have
developed novel technologies and devices to improve the overall
quality of life of affected patient population.
 For instance, in May 2019, Nevro Corp. launched the Senza Omnia
Spinal Cord Stimulation (SCS) System in the U.S. Omnia is the first and
the only spinal cord stimulation system designed to deliver its
proprietary HF10 therapy along with all other available spinal cord
stimulator frequencies. In January 2017, Abbott Laboratories launched
the new Proclaim DRG neurostimulation system in Europe.
 The Proclaim DRG neurostimulation system is designed to deliver dorsal
root ganglion (DRG) stimulation for patients suffering from chronic
neuropathic pain. Abbott is the first and only company that offers DRG
therapy and targeted relief for certain types of chronic pain.